DDInter1955 DDInter1435
Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Zafirlukast {u} (Compound) resembles {v} (Compound) Tolvaptan
Zafirlukast {u} (Compound) treats {v} (Disease) asthma
Zafirlukast {u} (Compound) binds {v} (Gene) CYSLTR2
Zafirlukast {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Zafirlukast {u} (Compound) causes {v} (Side Effect) Hyperbilirubinaemia
Zafirlukast {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Zafirlukast {u} may cause a minor interaction that can limit clinical effects when taken with {v} Citalopram
Zafirlukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilpivirine
Zafirlukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Zafirlukast {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Zafirlukast (Compound) resembles Tolvaptan (Compound)
Zafirlukast (Compound) treats asthma (Disease)
Zafirlukast (Compound) binds CYSLTR2 (Gene)
Zafirlukast (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class)
Zafirlukast (Compound) causes Hyperbilirubinaemia (Side Effect)
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Donepezil
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Citalopram
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib
Zafirlukast may lead to a major life threatening interaction when taken with Lomitapide